Beacon Biosignals Secures $86M in Funding to Advance AI-Driven Brain Biomarkers and Partner with Half of World’s Top 10 Pharma Companies

Nov 13, 2025 18:31 CST Updated 18:31

Beacon Biosignals

Developer of AI Platform for Neurological and Psychiatric Disorders Treatment

It is reported that AI medical company Beacon BiosignalsCompleted$86 million(Approximately RMB 610 million)Financing.

This round of funding will be used forBuild an EEG dataset to promote new drugs and diagnostics for neurological diseases.

Beacon Biosignals, Inc. was founded in 2019 as an AI-driven neurotechnology company dedicated to transforming the development of treatments for neurological, psychiatric, and sleep disorders.

The company is utilizingAdvanced Machine Learning and Artificial IntelligenceTechnology to decode complex neurophysiological data, particularly electroencephalogram (EEG) data, aiming to provide more accurate diagnoses and actionable insights for brain disorders.

Beacon Biosignals has a portable device for measuring EEG data, which is able toProvide more objective measurements and record brain electrical activity.

In recent years, the drug development market for neurological diseases has witnessed a revival.

After decades of setbacks, the field has regained market attention with the approval of new treatments for Alzheimer's disease and schizophrenia.

However, a key issue remains: the current methods for measuring the impact of drugs on brain function are inconsistent.

Unlike cancer, where scientists can use the shrinkage or disappearance of tumors as evidence of a drug's effectiveness, drugs for neurological diseases rely on more subjective measures from patients.

Currently,Beacon Biosignals is collaborating withCollaborate with biopharmaceutical companies and train artificial intelligence to generate better biomarkers for neurological diseases.

Last year, Beacon Biosignals announced that it was collaborating with Takeda to treat sleep disorders. In addition, the founder revealed that Beacon Biosignals has partnered with five of the top ten pharmaceutical companies.

Traditionally, EEG data is collected in laboratories, but Beacon's portable devices can not only measure brain waves but also be used at home.

After obtaining EEG data, the company uses artificial intelligence algorithms to gain insights into the biological information and develop better diagnostic methods for neurological diseases.

Currently, Beacon's equipment has been used in 28 A total of 7 phase 3 studies among clinical trials. This involves a range of diseases, including narcolepsy, depression, and Parkinson's disease.

—END—